Two large-scale phase 3 trials found that semaglutide did not significantly slow cognitive decline in early-stage Alzheimer’s disease despite improving bio

GLP-1 drugs like Wegovy and Zepbound have been racking up sales and new indications, as researchers learn more about how the drugs affect the body beyond just weight loss. But one of the more anticipated studies exploring how they impact Alzheimer’s disease has found no meaningful effect, Novo Nordisk said in a press release on Nov. 24

AN ‘invisible fat’ hidden deep within the body can age the brain and raise the risk of Alzheimer’s, according to new research. Known as visceral fat, you can’t see or feel

Weight loss is usually considered a good thing, unexpected and extreme weight loss can be a sign of something in your body going very wrong. There could be some underlying issues that are causing your body to pull weight and nutrition from your muscles and ...

Nick Blackmer is a librarian, fact-checker, and researcher with more than 20 years of experience in consumer-facing health and wellness content. Primarily prescribed for type 2 diabetes and weight loss, medications like Ozempic and Zepbound are also ...

Studies from Novo Nordisk due early next month will give the strongest indication yet of whether blockbuster GLP-1 drugs - a class being used by millions for diabetes and weight loss - can slow progress of Alzheimer's disease.